key: cord-0713750-4cy5ucw7 authors: Palich, R.; Veyri, M.; Vozy, A.; Marot, S.; Gligorov, J.; Benderra, M.-A.; Maingon, P.; Morand-Joubert, L.; Adjoutah, Z.; Marcelin, A.-G.; Spano, J.-P.; Barrière, J. title: High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated by chemotherapy for solid cancers date: 2021-06-22 journal: Ann Oncol DOI: 10.1016/j.annonc.2021.06.018 sha: d27b4cd56bbd7e64cd750c3e92521faf2d06e51c doc_id: 713750 cord_uid: 4cy5ucw7 nan Anti-spike antibody titer (UA/mL) Anti-spike antibody titer (U/mL) Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study Weak immunogenicity after a single dose of SARS CoV-2 mRNA vaccine in treated cancer patients anti-SARS-CoV-2 vaccine in patients treated for solid tumors SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. The Lancet